Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study DOI Creative Commons
Dimitrios Basoulis,

Elpida Mastrogianni,

Georgios Karamanakos

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(8), P. 1345 - 1345

Published: Aug. 22, 2024

Background: COVID-19 continues to pose a threat immunocompromised individuals, even with vaccination. The monoclonal antibodies (mAbs) tixagevimab/cilgavimab (TXG/CIL) provide targeted prophylaxis against SARS-CoV-2 the benefit of prolonged half-life. Although approved for prevention, there is limited data on their effectiveness among heavily populations. Methods: We conducted prospective, observational study at Laiko General Hospital, Athens, Greece, from August December 2022 investigate efficacy TXG/CIL as form pre-exposure in patients. Data breakthrough infections were collected over six-month follow-up period. Results: Of 375 participants (mean age 61.3 ± 14.1 years; 59.7% male), 76 (20.3%) developed infections, an incidence 3.81 cases/100 patient months. Hospitalization was required 21 patients (5.6%), median stay 14 days. Seven deaths recorded, only one attributed COVID-19. Previous infection (OR 0.46, 95% CI 0.26–0.82) and hybrid immunity 0.52, 0.29–0.92) can protect new infection. Solid organ malignancy significantly increased risk severe outcomes those infected 7.4, 2.2–24.7, p = 0.001). Conclusions: provides effective Future strategies should focus developing mAb combinations address emerging variants vulnerable

Language: Английский

Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study DOI Creative Commons
Dimitrios Basoulis,

Elpida Mastrogianni,

Georgios Karamanakos

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(8), P. 1345 - 1345

Published: Aug. 22, 2024

Background: COVID-19 continues to pose a threat immunocompromised individuals, even with vaccination. The monoclonal antibodies (mAbs) tixagevimab/cilgavimab (TXG/CIL) provide targeted prophylaxis against SARS-CoV-2 the benefit of prolonged half-life. Although approved for prevention, there is limited data on their effectiveness among heavily populations. Methods: We conducted prospective, observational study at Laiko General Hospital, Athens, Greece, from August December 2022 investigate efficacy TXG/CIL as form pre-exposure in patients. Data breakthrough infections were collected over six-month follow-up period. Results: Of 375 participants (mean age 61.3 ± 14.1 years; 59.7% male), 76 (20.3%) developed infections, an incidence 3.81 cases/100 patient months. Hospitalization was required 21 patients (5.6%), median stay 14 days. Seven deaths recorded, only one attributed COVID-19. Previous infection (OR 0.46, 95% CI 0.26–0.82) and hybrid immunity 0.52, 0.29–0.92) can protect new infection. Solid organ malignancy significantly increased risk severe outcomes those infected 7.4, 2.2–24.7, p = 0.001). Conclusions: provides effective Future strategies should focus developing mAb combinations address emerging variants vulnerable

Language: Английский

Citations

0